(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-1.33% € 118.80
Live Chart Being Loaded With Signals
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines...
Stats | |
---|---|
Объем за сегодня | 748.00 |
Средний объем | 970.00 |
Рыночная капитализация | 300.88B |
EPS | €0 ( 2024-04-24 ) |
Дата следующего отчета о доходах | ( €0 ) 2024-05-28 |
Last Dividend | €0.730 ( 2023-09-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 141.43 |
ATR14 | €0.579 (0.49%) |
Merck & Co Inc Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Merck & Co Inc Финансовые показатели
Annual | 2023 |
Выручка: | €60.12B |
Валовая прибыль: | €43.99B (73.17 %) |
EPS: | €0.140 |
FY | 2023 |
Выручка: | €60.12B |
Валовая прибыль: | €43.99B (73.17 %) |
EPS: | €0.140 |
FY | 2022 |
Выручка: | €59.28B |
Валовая прибыль: | €41.87B (70.63 %) |
EPS: | €5.72 |
FY | 2021 |
Выручка: | €48.70B |
Валовая прибыль: | €35.08B (72.02 %) |
EPS: | €5.14 |
Financial Reports:
No articles found.
Merck & Co Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.690 (N/A) |
€0.730 (N/A) |
€0.730 (N/A) |
€0.730 (N/A) |
€0.730 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.380 | 2009-12-11 |
Last Dividend | €0.730 | 2023-09-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 56 | -- |
Total Paid Out | €28.56 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.54 | -- |
Div. Sustainability Score | 3.16 | |
Div.Growth Potential Score | 6.70 | |
Div. Directional Score | 4.93 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
IC1B.F | Ex Dividend Junior | 2023-08-31 | Annually | 0 | 0.00% | |
SYZ.DE | Ex Dividend Junior | 2023-07-12 | Annually | 0 | 0.00% | |
CIS.DE | Ex Dividend Knight | 2023-10-03 | Quarterly | 0 | 0.00% | |
LLY.DE | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% | |
VOS.DE | Ex Dividend Junior | 2023-05-25 | Sporadic | 0 | 0.00% | |
EBA.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
NVD.DE | Ex Dividend Knight | 2023-09-06 | Quarterly | 0 | 0.00% | |
8GM.DE | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
GDX.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
R66.DE | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0376 | 1.500 | 9.25 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0595 | 1.500 | -0.451 | -0.676 | [0.1 - 1] |
payoutRatioTTM | 2.42 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 6.41 | 1.000 | 8.74 | 8.74 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.58 | 2.00 | 8.47 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.46 | 2.00 | 8.27 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.746 | 1.000 | 0.908 | 0.908 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0944 | 1.000 | -0.111 | -0.111 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.16 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 141.23 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0595 | 2.50 | -0.290 | -0.676 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.46 | 2.00 | 8.85 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.35 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.58 | 2.00 | 8.47 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.42 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 7.08 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.190 | 1.000 | 7.75 | 0 | [0.1 - 0.5] |
Total Score | 6.70 |
Merck & Co Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа